Home › Merck Animal Health Receives FDA Approval of BRAVECTO (fluralaner topical solution) for Cats and Dogs
 

Keywords :   


Merck Animal Health Receives FDA Approval of BRAVECTO (fluralaner topical solution) for Cats and Dogs

2016-07-21 23:00:00| Merck.com - Corporate News

Dateline City: MADISON, N.J. Topical Treatment for Fleas and Ticks Effective for up to 12 Weeks MADISON, N.J.--(BUSINESS WIRE)--Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, today announced the U.S. Food and Drug Administrations approval of BRAVECTO (fluralaner topical solution) for both cats and dogs, a topical treatment for fleas and ticks effective for up to 12 weeks1,2 following a single dose. Language: English Contact: Merck Animal HealthMedia:Kelly Goss, 913-558-6452 kelly.goss@merck.com orPamela Eisele, 267-305-3558 pamela.eisele@merck.com orInvestor Relations:Amy Klug, 908-740-1898 amy.klug@merck.com Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: health solution animal approval

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
23.04Initiative Details Environmental Benefits of Recycling Aerosol Can Products
23.04Post Office boss obsessed with pay says ex-HR chief
23.04Nexxen empowers Australian advertisers using VIDAA ACR data
23.04Peloton Wellness Expert Matt Wilpers Teams Up with Indie Brand Oars + Alps
23.04FSEA releases new study on material sustainability
23.04Discovering Michigans Magic: Cassondra Wanders Adventure Series
23.04Siegwerk achieves EcoVadis Silver Medal for sustainability excellence
23.04Denmark\'s FlexoPrint adds second Mark Andy Digital Series press
More »